Barinthus Biotherapeutics plc
BRNS
$0.74
-$0.02-2.49%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -91.29% | 50.13% | 23.86% | 31.05% | -7.51% |
| Total Depreciation and Amortization | -14.06% | -17.15% | 205.94% | -91.59% | -2.67% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | -25.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | 222.03% | -136.31% | -43.17% | 37.02% | 12.74% |
| Change in Net Operating Assets | -74.70% | -35.51% | 335.16% | 33.48% | -1,504.38% |
| Cash from Operations | -140.37% | 20.65% | 60.45% | 40.77% | -21.52% |
| Capital Expenditure | -- | -- | -- | 100.00% | -540.00% |
| Sale of Property, Plant, and Equipment | 10.91% | 2,650.00% | -99.56% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 10.91% | 2,650.00% | -99.56% | 1,509.38% | -540.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -100.00% |
| Foreign Exchange rate Adjustments | 134.84% | -423.44% | 122.78% | -134.32% | 73.35% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -62.11% | -22.00% | 68.44% | 5.35% | -8.24% |